

LETTER TO THE EDITOR

Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?

Gavin Hudson,¹ Catherine Mowbray,¹ Joanna L. Elson,¹ Anu Jacob,² Michael Boggild,² Antonio Torroni³ and Patrick F. Chinnery^{1,4}

¹Mitochondrial Research Group, Newcastle University, ²The Walton Centre, Liverpool, UK, ³Dipartimento di Genetica e Microbiologia, Università di Pavia, Pavia, Italy and ⁴Institute of Human Genetics, Newcastle University, UK

Correspondence to: Prof. P. F. Chinnery, M4014, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
E-mail: P.F.Chinnery@ncl.ac.uk
doi:10.1093/brain/awm224

Received June 28, 2007. Revised August 19, 2007. Accepted August 21, 2007. Advance Access publication October 29, 2007.

Neuromyelitis optica (NMO), or Devic's disease, is a relapsing demyelinating disease of the central nervous system characterized by optic neuritis and myelitis with distinct clinical, imaging, CSF and serological features (Wingerchuk *et al.*, 2006). There is increasing evidence that NMO is an antibody-mediated organ-specific autoimmune disease associated with anti-aquaporin 4 antibodies detectable in serum (Lennon *et al.*, 2004), supported by four recent papers in the same edition of *Brain* (Matsuoka *et al.*, 2007; Misu *et al.*, 2007; Roemer *et al.*, 2007; Takahashi *et al.*, 2007) and the accompanying scientific commentary (Compston, 2007). However, it is still not known why the disorder specifically targets the optic nerves and spinal cord. Several siblings with NMO have been reported (McAlpine, 1938; Keegan and Weinshenker, 2000; Yamakawa *et al.*, 2000), raising the possibility of a genetic predisposition, but no pathogenic mutations have been identified in the *AQP4* gene on chromosome 18q11.2-q12.1 (Lu *et al.*, 1996).

NMO has similarities with Leber hereditary optic neuropathy (LHON, MIM 535 000) which is primarily due to mutations of mitochondrial DNA (mtDNA) that disrupt complex I of the respiratory chain (Carelli *et al.*, 2004). Although the genetic defect in LHON is present in all tissues, the pathology also is strikingly tissue-specific. Most affected individuals develop sub-acute painless visual failure due to focal involvement of both optic nerves (Newman *et al.*, 1991; Riordan-Eva *et al.*, 1995), but some also develop a progressive myelopathy, with high signal extending over multiple spinal levels on MR imaging, and the absence of oligoclonal bands in the CSF (Johns *et al.*, 1991; Jaros *et al.*, 2007). Tissue-specific susceptibility to mitochondrial dysfunction is thought to explain why the neurodegeneration in LHON only affects specific neuronal

pathways, and recent evidence implicates a similar mechanism in the axonal loss that follows acute inflammatory lesions in multiple sclerosis (MS) (Dutta *et al.*, 2006).

A further link between LHON and central nervous system demyelination is the MS-like illness first described in women harbouring LHON mtDNA mutations (Harding *et al.*, 1992), characterized by severe and often irreversible bilateral visual failure. Patients with LHON-MS have typical brain imaging and unmatched oligoclonal bands in the cerebrospinal fluid (Riordan-Eva *et al.*, 1995). Although the majority of cases are female, males have been described with each of the common LHON mtDNA mutations (Lees *et al.*, 1964; Flanigan and Johns, 1993; Kellar-Wood *et al.*, 1994; Olsen *et al.*, 1995; Jansen *et al.*, 1996; Leuzzi *et al.*, 1997; Horvath *et al.*, 2000; Buhmann *et al.*, 2002).

Given the clinical similarities between NMO and LHON, previous investigators have looked for specific mtDNA mutations in a small number of patients with NMO (Johns *et al.*, 1991; Cock *et al.*, 1997; Kalman and Mandler, 2002; Ghezzi *et al.*, 2004), and others have studied polymorphic variation of mtDNA in NMO cases (Cock *et al.*, 1997; Kalman *et al.*, 1999; Kalman and Mandler, 2002; Celebisoy *et al.*, 2006). However, the largest case series only included four patients, so the role of mtDNA in the etiology of NMO has yet to be resolved. To address this issue we studied the mtDNA of 32 British patients with NMO fulfilling recent diagnostic criteria (Wingerchuk *et al.*, 2006). These patients are part of the United Kingdom NMO study cohort co-collected through the British Neurological Surveillance Unit (Jacob *et al.*, 2005). Two different hypotheses were tested: (i) that highly deleterious pathogenic LHON mtDNA mutations are a common cause of NMO; and, (ii) that mtDNA polymorphisms are associated with NMO. We consciously limited our study to patients

of European maternal ancestry to allow interpretation of the mtDNA genetic background in an appropriate population context.

Are pathogenic LHON mtDNA mutations a common cause of NMO?

We sequenced the *MTND1*, *MTND4* and *MTND6* genes which are known to harbour the vast majority (>99%) of LHON mutations, including the three most common: m.3260G>A, m.11778G>A, and m.14484T>C (Mackey *et al.*, 1996), and other primary pathogenic mutations found within the ND6 “hotspot” (Chinnery *et al.*, 2001). No LHON or other known pathogenic mutations were identified in the 32 NMO cases.

Are mtDNA polymorphisms associated with NMO?

There are a number of different ways that polymorphic variation of mtDNA could be associated with NMO. Human mtDNA is maternally inherited and has acquired extensive variation over time. Substitutions acquired >10 000 years before the present subdivide the phylogeny into a number of discrete clades called haplogroups. Specific haplogroups are preferentially associated with mtDNA mutations that cause LHON, and increase the clinical penetrance of the disorder (Brown *et al.*, 1997; Man *et al.*, 2004). Sub-haplogroup J1 is associated with an increased risk of visual failure in m.14484T>C pedigrees, and J2 is associated with an increased risk of visual failure in m.11778G>A pedigrees (Carelli *et al.*, 2006; Hudson *et al.*, 2007).

Epidemiological evidence has led to the suggestion that NMO is a prototypic form of MS which emerged out of Africa, and was shaped into its current form through a gene-environment interaction between Human leukocyte antigens and Epstein-Barr virus, either through genetic hitch-hiking or in parallel to the emergence of mtDNA haplogroup J from Western Asia (Compston, 2004; Cox *et al.*, 2005). In keeping with this, small studies have reported an association between optico-spinal MS and haplogroup J (Mayr-Wohlfart *et al.*, 1996; Reynier *et al.*, 1999; Kalman and Mandler, 2002), although this has not been a universal finding (Otaegui *et al.*, 2004).

To determine whether these deep-rooted haplogroup-defining polymorphisms are associated with NMO, the mtDNA haplogroup was defined in all 32 NMO cases by PCR-RFLP analysis (Torroni *et al.*, 1997), and compared to 1010 British controls (part of the 1958 UK-MRC birth cohort, Table 1). There was no significant difference in the overall haplogroup distribution (Exact *P*=0.117), nor in the frequency of the individual haplogroups (Table 1). Direct sequencing of the mtDNA regions encompassing nucleotides 3010 (3010 in J1) and 15257 (15257A in J2)

Table 1 Haplogroup distribution for 32 patients with neuromyelitis optica and 1010 controls

Study Group	Haplogroup										TOTAL	
	H	T	J	K	U (w/o K)	I	W	V	X	M		Other
Neuromyelitis optica patients	16	3	1	1	5	1	2	0	1	1	1	32
Percentage (%)	50.0	9.4	3.1	3.1	15.6	3.1	6.3	0	3.1	3.1	3.1	
95% CI	33.63–66.37	2.46–25.00	0–17.11	0–17.11	6.39–32.23	0–17.11	0.72–21.16	0–12.73	0–17.11	0–17.11	0–17.11	
Controls Subjects	448	99	123	91	119	33	11	32	15	6	33	1010
Percentage (%)	44.0	9.8	12.2	9.0	11.8	3.3	1.1	3.2	1.5	0.6	3.3	
95% CI	41.26–47.48	8.04–11.80	10.22–14.36	7.32–10.95	9.86–13.93	2.32–4.56	0.54–1.94	2.18–4.44	0.83–2.44	0.22–1.29	2.26–4.56	
P-Value	0.577	1.00	0.166	0.355	0.588	1.00	0.051	0.607	0.424	0.18	1.00	

Ninety five percent confidence intervals (CI) calculated according to the Clopper-Pearson method. P-value = empirical P-value determined by Monte-Carlo simulation with 1000 iterations based on the method of Roff and Bentzen (1989) as described in Samuels *et al.* (2006). For historical reasons, haplogroups K and U are shown separately, but K is a sub-haplogroup of U. W/o = without, “Other” refers to European subjects who could not be classified into one of the ten major European haplogroups.

Table 2 *MTCYB* substitutions in 32 cases of neuromyelitis optica

Patient code	MtDNA Haplogroup	<i>MTCYB</i> substitutions						
1	H	m.I5326A>G						
3	H	m.I5326A>G						
4	H	m.I5326A>G						
6	H	m.I5326A>G						
7	H	m.I5326A>G						
14	H	m.I5326A>G						
16	H							
17	H	m.I5326A>G						
18	H	m.I5326A>G						
19	H	m.I500IT>G m.I5326A>G						
24	H	m.I500IT>G m.I5326A>G						
29	H	m.I5326A>G						
72	H	m.I5326A>G						
80	H	m.I5064A>G m.I5326A>G m.I5833C>T						
86	H	m.I5326A>G						
88	H	m.I5326A>G						
36	I	m.I4766C>T m.I4927A>G m.I5043G>A m.I5317G>A m.I5326A>G m.I5758A>G						
85	J	m.I4766C>T m.I4798T>C m.I5326A>G m.I5452C>A						
66	K	m.I4766C>T m.I4798T>C m.I5326A>G						
64	M	m.I4766C>T m.I4783T>C m.I4803C>T m.I5043G>A m.I5301G>A m.I5326A>G						
33	T	m.I4766C>T m.I4905G>A m.I5326A>G m.I5452C>A m.I5607A>G						
52	T	m.I4766C>T m.I4905G>A m.I5326A>G m.I5452C>A m.I5607A>G						
56	T	m.I4766C>T m.I4905G>A m.I5326A>G m.I5452C>A m.I5607A>G						
5	U	m.I4766C>T m.I5326A>G m.I5631A>G m.I5721T>C						
34	U	m.I4766C>T m.I4793A>G m.I5218A>G m.I5317G>A m.I5326A>G m.I5767C>T						
59	U	m.I4766C>T m.I5326A>G						
70	U	m.I4766C>T m.I5326A>G						
75	U	m.I4766C>T m.I4793A>G m.I5218A>G m.I5326A>G						
49	W	m.I4766C>T m.I5326A>G						
77	W	m.I4766C>T m.I5326A>G						
31	X	m.I4766C>T m.I5326A>G						
58	Other	m.I5326A>G						

(relative to the revised Cambridge reference sequence for mtDNA, Andrews *et al.*, 1999).

revealed that the one haplogroup J case of NMO belonged to sub-haplogroup J1c.

Recent phylogenetic analysis and association studies of extensive LHON pedigrees suggests that substitutions in the mtDNA gene coding for cytochrome *b*, *MTCYB*, are responsible for the increased risk of visual failure in haplogroup J m.11778G>A and m.14484T>C pedigrees (Carelli *et al.*, 2006; Hudson *et al.*, 2007). This may arise through the interaction between complex I and III (cyt *b*) subunits in super-complexes (Schagger and Pfeiffer, 2000), or the cumulative effect of deleterious mutations affecting serial components of the respiratory chain. We therefore sequenced the entire *MTCYB* gene in the 32 NMO patients and compared the result to 100 datasets of 32 randomly selected healthy control subjects identified from a subgroup of 527 healthy controls within MitoKor database (Herrnstadt *et al.*, 2002), calculating the number of synonymous, non-synonymous and the total number substitutions in *MTCYB* (Table 2, Fig. 1). The total number of *MTCYB* substitutions in the 32 NMO cases fell within the range of control values (Fig. 1a). Likewise, the number of synonymous and non-synonymous *MTCYB* changes in the NMO patients fell within the control range

(Fig. 1b and 1c), as did the ratio of synonymous to non-synonymous substitutions (Fig. 1d), providing evidence against the hypothesis that the accumulation of deleterious substitutions predicted to alter cyt *b* function predisposes to NMO.

In conclusion, we found no evidence to support the hypothesis that ancient mtDNA polymorphisms are associated with or predispose to NMO. A study of this size cannot exclude a subtle increased susceptibility, especially if conferred by rare mtDNA variants in a region not directly sequenced here. However, this would be very difficult to demonstrate, given the rarity of NMO and the samples sizes required to show a convincing association between mtDNA variants and a complex disease (Samuels *et al.*, 2006).

Acknowledgements

PFC is a Wellcome Trust Senior Fellow in Clinical Science who also receives funding from the United Mitochondrial Diseases Foundation, a research grant from The United States Army, the Parkinson's Disease Society (UK), and the EU FP program EUMitocombat and MITOCIRCLE.




Fig. 1 Frequency distribution histograms showing the number *MTCYB* substitutions relative to the revised Cambridge reference sequence of mitochondrial DNA (Andrews *et al.*, 1999) in 100 randomly selected control subjects from a subgroup of 527 controls from the MitoKor database (Herrnstadt *et al.*, 2002): (a) total number of substitutions, (b) number of synonymous substitutions, (c) number of non synonymous substitutions, (d) the ratio of non-synonymous (N_a) to synonymous (N_s) substitutions in *MTCYB*. The corresponding value for the 32 patients with NMO is shown on each distribution with an arrow.

Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.

References

- Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA [letter]. *Nat Genet* 1999; 23: 147.
- Brown MD, Sun F, Wallace DC. Clustering of Caucasian Leber hereditary optic neuropathy patients containing the 11778 or 14484 mutations on an mtDNA lineage. *Am J Hum Genet* 1997; 60: 381–7.
- Buhmann C, Gbadamosi J, Heesen C. Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy. *Acta Neurol Scand* 2002; 106: 236–9.
- Carelli V, Achilli A, Valentino ML, Rengo C, Semino O, Pala M, *et al.* Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. *Am J Hum Genet* 2006; 78: 564–74.
- Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. *Prog Retin Eye Res* 2004; 23: 53–89.
- Celebisoy N, Akyurekli O, Copur A. Devic's neuromyelitis optica: a case with mitochondrial DNA mutations. *Eur Neurol* 2006; 55: 93–5.
- Chinnery PF, Brown DT, Andrews RM, Singh-Kler R, Riordan-Eva P, Lindley J, *et al.* The mitochondrial ND6 gene is a hotspot for mutations that cause Leber's hereditary optic neuropathy. *Brain* 2001; 124: 209–18.
- Cock H, Mandler R, Ahmed W, Schapira AH. Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. *J Neurol Neurosurg Psych* 1997; 62: 85–7.
- Compston A. 'The marvellous harmony of the nervous parts': the origins of multiple sclerosis. *Clin Med* 2004; 4: 346–54.
- Compston A. Complexity and heterogeneity in demyelinating disease. *Brain* 2007; 130: 1178–80.
- Cox A, Coles A, Antoun N, Malik O, Lucchinetti C, Compston A. Recurrent myelitis and optic neuritis in a 29-year-old woman. *Lancet Neurol* 2005; 4: 510–6.
- Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, *et al.* Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. *Ann Neurol* 2006; 59: 478–89.
- Flanigan KM, Johns DR. Association of the 11778 mitochondrial DNA mutation and demyelinating disease. *Neurology* 1993; 43: 2720–2.

- Ghezzi A, Baldini S, Zaffaroni M, Leoni G, Koudriavtseva T, Casini AR, et al. Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report. *Neurol Sci* 2004; 25 Suppl 4: S380–2.
- Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellar-Wood H, Menard D, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. *Brain* 1992; 115: 979–89.
- Herrnstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, Anderson S, et al. Reduced median network analysis of complete mtDNA coding region sequences for the major African, Asian, and European haplogroups. *Am J Hum Genet* 2002; 70: 1152–71.
- Horvath R, Abicht A, Shoubridge EA, Karcagi V, Rozsa C, Komoly S, et al. Leber's hereditary optic neuropathy presenting as multiple-sclerosis like illness. *J Neurol* 2000; 247: 65–7.
- Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. *Am J Hum Genet* 2007; 81: 228–33.
- Jacob A, Nicholas R, Das K, Boggild M. Neuromyelitis optica in the UK clinical, epidemiological, radiological and treatment profile; Proceedings of the Association of British Neurologists, Queens University of Belfast, Ireland. *J Neurol Neurosurg Psych* 2005; 76: 1313–26.
- Jansen PH, van der Knaap MS, de Coo IF. Leber's hereditary optic neuropathy with the 11778 mtDNA mutation and white matter disease resembling multiple sclerosis: clinical, MRI and MRS findings. *J Neurol Sci* 1996; 135: 176–80.
- Jaros E, Mahad D, Hudson G, Birchall D, Sawcer SJ, Griffiths PG, et al. Primary spinal cord neurodegeneration in Leber hereditary optic neuropathy. *Neurology* 2007; 69: 214–6.
- Johns DR, Hurko O, Attardi G, Griffin JW. Molecular basis of a new mitochondrial disease: acute neuropathy and myelopathy. *Ann Neurol* 1991; 30: 234.
- Kalman B, Li S, Chatterjee D, O'Connor J, Voehl MR, Brown MD, et al. Large scale screening of the mitochondrial DNA reveals no pathogenic mutations but a haplotype associated with multiple sclerosis in Caucasians. *Acta Neurol Scand* 1999; 99: 16–25.
- Kalman B, Mandler RN. Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations, but polymorphisms also found in association with multiple sclerosis. *Ann Neurol* 2002; 51: 661–2.
- Keegan M, Weinshenker B. Familial Devic's disease. *Can J Neurol Sci* 2000; 27: S57–58.
- Kellar-Wood H, Robertson N, Govan GG, Compston DA, Harding AE. Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. *Ann Neurol* 1994; 36: 109–12.
- Lees F, Macdonald AM, Turner JW. Leber's disease with symptoms resembling disseminated sclerosis. *J Neurol Neurosurg Psych* 1964; 27: 415–21.
- Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet* 2004; 364: 2106–12.
- Leuzzi V, Carducci C, Lenza M, Salvetti M, Ristori G, Di Giovanni S, et al. LHON mutations in Italian patients affected by multiple sclerosis. *Acta Neurol Scand* 1997; 96: 145–8.
- Lu M, Lee MD, Smith BL, Jung JS, Agre P, Verdijk MA, et al. The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. *Proc Natl Acad Sci USA* 1996; 93: 10908–12.
- Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, et al. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. *Am J Hum Genet* 1996; 59: 481–5.
- Man PY, Howell N, Mackey DA, Norby S, Rosenberg T, Turnbull DM, et al. Mitochondrial DNA haplogroup distribution within Leber hereditary optic neuropathy pedigrees. *J Med Genet* 2004; 41: e41.
- Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. *Brain* 2007; 130: 1206–23.
- Mayr-Wohlfart U, Paulus C, Henneberg A, Rodel G. Mitochondrial DNA mutations in multiple sclerosis patients with severe optic involvement. *Acta Neurol Scand* 1996; 94: 167–71.
- McAlpine D. Familial Neuromyelitis Optica: its occurrence in identical twins. *Brain* 1938; 61: 430–48.
- Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. *Brain* 2007; 130: 1224–34.
- Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. *Am J Ophthalmol* 1991; 111: 750–62.
- Olsen NK, Hansen AW, Norby S, Edal AL, Jorgensen JR, Rosenberg T. Leber's hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation. *Acta Neurol Scand* 1995; 91: 326–9.
- Otaegui D, Saenz A, Martinez-Zabaleta M, Villoslada P, Fernandez-Manchola I, Alvarez de Arcaya A, et al. Mitochondrial haplogroups in Basque multiple sclerosis patients. *Mult Scler* 2004; 10: 532–5.
- Reynier P, Penisson-Besnier I, Moreau C, Savagner F, Vielle B, Emile J, et al. mtDNA haplogroup J: a contributing factor of optic neuritis. *Eur J Hum Genet* 1999; 7: 404–6.
- Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. *Brain* 1995; 118: 319–37.
- Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. *Brain* 2007; 130: 1194–205.
- Roff DA, Bentzen P. The statistical analysis of mitochondrial DNA polymorphisms: chi 2 and the problem of small samples. *Mol Biol Evol* 1989; 6: 539–45.
- Samuels DC, Carothers AD, Horton R, Chinnery PF. The power to detect disease associations with mitochondrial DNA haplogroups. *Am J Hum Genet* 2006; 78: 713–20.
- Schagger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. *EMBO J* 2000; 19: 1777–83.
- Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. *Brain* 2007; 130: 1235–43.
- Torroni A, Petrozzi M, D'Urbano L, Sellitto D, Zeviani M, Carrara F, et al. Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484. *Am J Hum Genet* 1997; 60: 1107–21.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. *Neurology* 2006; 66: 1485–9.
- Yamakawa K, Kuroda H, Fujihara K, Sato S, Nakashima I, Takeda A, et al. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. *Neurology* 2000; 55: 318–20.